CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 15 enrolled
Drug / intervention
PF-04191834 +4 moredrug
Likely dose
PF-04191834 30mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00723021
NCT00723021Phase 2Completed

A Phase 2a, Randomised, Double-Blind (3rd Party Open), Double-Dummy, Placebo And Active Controlled 5-Way Crossover Study To Assess The Bronchodilatory Action, Safety, Toleration And Pharmacokinetics Of Single Oral Doses Of PF-04191834 In Asthmatic Patients.

Pfizer·interventional·Posted Jul 28, 2008·Updated Feb 1, 2013

In Brief

A Phase 2 clinical trial evaluating PF-04191834, zileuton, and 1 other intervention for Asthma. Completed, enrolled 15 participants across 4 sites.

Detailed Summary

Study to determine the bronchodilatory effects of PF-04191834 compared with zileuton in patients with asthma

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 28, 2008
Enrollment StartJul 1, 2008
Primary CompletionDec 1, 2008
Study CompletionJul 1, 2009
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 17.9 years ago

Interventions

PF-04191834drug

30mg PF-04191834, single dose, oral dispersion + 2 x placebo tablets.

PF-04191834drug

100mg PF-04191834, single dose, oral dispersion + 2 x placebo tablets, single dose.

PF-04191834drug

2000mg PF-04191834, single dose, oral dispersion + 2 x placebo tables, single dose

zileutondrug

1200mg, 2 x 600mg tablets, single dose + placebo oral dispersion, single dose.

Placebodrug

2 x placebo tablets + placebo oral dispersion, single dose.